Drug-induced thrombocytopenia – etiology and alternative therapeutic approaches
DOI:
https://doi.org/10.15584/ejcem.2023.3.15Keywords:
alternative therapeutics, drug-induced thrombocytopenia, phytochemicals, plateletsAbstract
Introduction and aim. The cumulative incidence of drug-induced thrombocytopenia (DIT) is 10 cases per one million people per year with a prevalence of approximately 25% in critically ill patients. This review provides a comprehensive view of drug-induced thrombocytopenia, diagnosis, underlying mechanisms, common strategies in therapeutics, and potential alternatives.
Material and methods. Databases such as “Google Scholar”, “PubMed”, “Medline” and “MDPI” was used for literature review with the keywords, “platelets”, “platelet disorders”, “thrombocytopenia”, “drug-induced”, “oxidative stress” “plant extracts”, “phytochemicals”, “antioxidants”, for the articles published between 2013-2023 and written in the English language.
Analysis of the literature. Several antimicrobials, anti-cancer drugs, and antivirals are often reported to cause adverse effects during treatment, such as thrombocytopenia. A thorough understanding of the underlying pathophysiology is important for appropriate treatment. Even though an improvement in platelet count is observed after the discontinuation of the causative drug, there is a dire need for treatment in some cases due to associated complications. There are various pitfalls with conventional treatments which include clinical complications and lack of effectiveness.
Conclusion. Interventions in therapeutics through antioxidants can aid in faster recovery. Various plant extracts and phytochemicals have been employed as therapeutics in platelet disorders due to their exceptional antioxidant activity. It is imperative to explore the bioactive components of natural products and their influence on platelet efficacy. Also, it highlights how antioxidants can be used as a safe, yet effective option as therapeutics for treating a complicated disorder such as DIT or be used as supplements to prevent adverse effects of existing treatments involving antibiotics and chemotherapeutics.
Downloads
References
van der Meijden PE, Heemskerk JW. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019;16:166-179. doi: 10.1038/s41569-018-0110-0
Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95:2514-2522. doi: 10.1182/blood.V95.8.2514
Laki K. Our ancient heritage in blood clotting and some of its consequences. Ann N Y Acad Sci. 1972;202:297-307. doi: 10.1111/j.1749-6632.1972.tb16342.x
Leslie M. Beyond Clotting: The Powers of Platelets. Science. 2010;328:562-564. doi: 10.1126/science.328.5978.562
Michelson, D A. Platelets. 3rd ed. USA:Academic Press;2013.
Krishnegowda M, Rajashekaraiah V. Platelet disorders: An overview. Blood Coagul Fibrin. 2015;26:479-491 . doi: 10.1097/01.mbc.0000469521.23628.2d
Hayward CPM, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia. 2006;12:128-136. doi: 10.1111/j.1365-2516.2006.01270.x
Schafer AI. Thrombocytosis. New Eng J Med. 2004;350:1211-1219. doi: 10.1056/NEJMra035363
Allen J, Stokol T. Thrombocytosis and Essential Thrombocythemia. In: Schalm’s Veterinary Hematology. Wiley; 2022. doi: 10.1002/9781119500537.ch82
Stasi R. How to approach thrombocytopenia. Hematology 2010, American Society of Hematology Education Program Book. 2012;1:191-197. doi: 10.1182/asheducation.V2012.1.191.3798260
Horrell CJ, Rothman J. The etiology of thrombocytopenia. Dimens Crit Care Nurs. 2001;20:10-16. doi: 10.1097/00003465-200107000-00004
Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics. Semin Thromb Hemost. 2020;46:264-274. doi: 10.1055/s-0039-1697930
Wang TL, Guo DH, Bai Y, Wen K, Han WY, Wang R. Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress. Clin Drug Investig. 2016;36:67-75. doi: 10.1007/s40261-015-0352-0
Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133:309–14. doi: 10.5858/133.2.309
Lu R, Lin Q, Chen S, Ye X. Chemotherapy-induced thrombocytopenia and platelet transfusion in patients with diffuse large B-cell lymphoma. Transl Cancer Res. 2020;9:1640-1651. doi: 10.21037/tcr.2020.01.64
Everds NE, Tarrant JM. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol. 2013;41:280-302. doi: 10.1177/0192623312467400
Tsappa I, Missouris C, Psarellis S. Acyclovir-induced thrombocytopenia in a patient with SLE. BMJ Case Rep. 2018;2018:bcr2018225118. doi: 10.1136/bcr-2018-225118
Crespillo-Andújar C, Calbacho Robles M, Norman FF, Pérez-Molina JA. Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease. BMJ Case Rep. 2018;2018:bcr2017223788. doi: 10.1136/bcr-2017-223788
Butt MU, Jabri A, Elayi SC. Azithromycin-Induced Thrombocytopenia: A Rare Etiology of Drug-Induced Immune Thrombocytopenia. Case Rep Med. 2019;2019:6109831. doi: 10.1155/2019/6109831
Beaulieu C, Kurczewski L, Yajnik V. Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia. J Thromb Thrombolysis. 2019;48:167-170. doi: 10.1007/s11239-019-01848-3
Savage-Elliott I, Wu VJ, Sanchez FL. Drug-Induced Thrombocytopenia Secondary to Commonly Used Antibiotics in Total Joint Arthroplasty. Arthroplast Today. 2020;6:137-140. doi: 10.1016/j.artd.2020.03.006
Alzahrani M, Alrumaih I, Alhamad F, Abdel Warith A. Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature. Platelets. 2018;29:628-631. doi: 10.1080/09537104.2018.1468025
Ramey C, LePera A. A Possible Case of Nitrofurantoin-Associated Immune Thrombocytopenia in a Healthy 45-Year-Old Caucasian Female. Cureus. 2023;15:e34654. doi: 10.7759/cureus.34654
Watanabe A, Momo K, Tanaka K, et al. Clinical course involving thrombocytosis and thrombocytopenia in a patient with bladder cancer treated with gemcitabine and cisplatin. Clin Case Rep. 2021;9:e05103. doi: 10.1002/ccr3.5103
Bancheno WM, Adidam SR, Melaku MA. Metastatic rectal neuroendocrine carcinoma presenting with treatment-refractory immune thrombocytopenia: A case report and literature review. Medicine. 2022;101:e29616. doi: 10.1097/MD.0000000000029616
Koehler A, Rao R, Rothman Y, et al. A Case Study Using Papaya Leaf Extract to Reverse Chemotherapy-Induced Thrombocytopenia in a GBM Patient. Integr Cancer Ther. 2022;21:153473542110684 . doi: 10.1177/15347354211068417
Ghazanfar H, Nawaz I, Ali N. Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms. Cureus. 2020;12:e9929. doi: 10.7759/cureus.9929
Xiaoqi Z, Shanshan J, Yuanyang P, Minfeng L, Changsheng Y, Jianyu D. Trastuzumab-Induced Severe Thrombocytopenia:A Case Report and Literature Review. Chin Med J. 2020;35:377. doi: 10.24920/003799
Dougherty SC, Lynch AC, Hall RD. Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use. Clin Case Rep. 2021;9:e04227. doi: 10.1093/ajcn/53.5.1222
Qiu G, Li S, Li B, et al. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report. Transl Lung Cancer Res. 2022;11:2346-2355. doi: 10.21037/tlcr-22-745
Jbara M, Bhogal S, Bajaj K, Chhabra L. Abciximab-induced delayed profound thrombocytopaenia. BMJ Case Rep. 2017;2017:bcr2017219379. doi: 10.1136/bcr-2017-219379
Ghuman J, Manasewitsch NT, Ghuman J, et al. Atorvastatin-Induced Refractory Thrombocytopenia. Cureus. 2021;13:e12502. doi: 10.7759/cureus.12502
Meghrajani V, Sabharwal N, Namana V, Elsheshtawy M, Topi B. A Case of Hyperacute Severe Thrombocytopenia Occurring Less than 24 Hours after Intravenous Tirofiban Infusion. Case Rep Hematol. 2018;2018:1-6. doi: 10.1155/2018/4357981
Alamin MA, Al-Mashdali A, Al Kindi DI, Elshaikh EA, Othman F. Eptifibatide-induced acute profound thrombocytopenia: A case report. Medicine. 2022;101:e28243. doi: 10.1097/MD.0000000000028243
Raimonde AR, Dennis AK. Carvedilol-Induced Thrombocytopenia: A Case Report. Hosp Pharm. 2022;57:786-789 . doi: 10.1177/00185787221108719
Lingamaneni P, Gonakoti S, Moturi K, Vohra I, Zia M. Heparin-Induced Thrombocytopenia in COVID-19. J Investig Med High Impact Case Rep. 2020;8:2324709620944091. doi: 10.1177/2324709620944091
Quintás-Cardama A, Santos FPDS, Kantarjian H, et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer. 2009;115:3935-3943. doi: 10.1002/cncr.24432
Majhail NS, Lichtin AE. What is the best way to determine if thrombocytopenia in a patient on multiple medications is drug-induced? Cleve Clin J Med. 2002;69:259-262. doi: 10.3949/ccjm.69.3.259
George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009;1:153-158. doi: 10.7326/0003-4819-129-11_Part_1-199812010-00009
Vayne C, Guéry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2020;9(7):2212. doi: 10.3390/jcm9072212
Manasa K, Soumya R, Vani R. Phytochemicals as potential therapeutics for thrombocytopenia. J Thromb Thrombolysis. 2016;41:436-440. doi: 10.1007/s11239-015-1257-8
Li MF, Li XL, Fan KL, et al. Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: An open-label, multicenter, randomized controlled trial. J Hematol Oncol. 2017;10:104. doi: 10.1186/s13045-017-0476-1
Cuker A. Toxicities of the Thrombopoietic Growth Factors. Semin Hematol. 2010;47:289-298. doi: 10.1053/j.seminhematol.2010.03.002
Zhang Y, Sun J, Tan M, et al. Species-Specific Involvement of Integrin aIIbß3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys. Mol Ther. 2018;26:1457-1470. doi: 10.1016/j.ymthe.2018.04.005
Machlus KR, Wu SK, Vijey P, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130:1132-1143. doi: 10.1182/blood-2016-11-752840
Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther. 2004;29:95-103. doi: 10.1111/j.1365-2710.2004.00543.x
Narayanan PK, Henry S, Li N. Drug-induced thrombocytopenia: mechanisms and relevance in preclinical safety assessment. Curr Opin Toxicol. 2019;17:23-30. doi: 10.1016/J.COTOX.2019.10.002
de Goeij BECG, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016;40:14-23. doi: 10.1016/J.COI.2016.02.008
Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003;21:3542. doi: 10.1200/JCO.2003.99.046
Mirabet M, Barrabés JA, Quiroga A, Garcia-Dorado D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol. 2008;45:937-944. doi: 10.1016/j.molimm.2007.08.006
Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood. 2002:99:2054-2059. doi: 10.1182/blood-2017-10-812461
Brunasso AMG, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-a agents for psoriasis. J Am Acad Dermatol. 2009;60:781-785. doi: 10.1016/j.jaad.2008.12.001
Keystone EC. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):427-443. doi: 10.1016/s0889-857x(05)70211-8
Santostefano MJ, Kirchner J, Vissinga C, et al. Off-Target Platelet Activation in Macaques Unique to a Therapeutic Monoclonal Antibody. Toxicol Pathol. 2012;40:899-917. doi: 10.1177/0192623312444029
Rudmann DG, Page TJ, Vahle JL, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012;125:586-594. doi: 10.1093/toxsci/kfr318
George JN, Medina PJ, Zondor SD. Treatment of drug-induced thrombocytopenia. Expert Opin Drug Saf. 2002;1:173-180. doi: 10.1517/14740338.1.2.173
Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology 2014. Hematology Am Soc Hematol Educ Program. 2018;2018:576-583. doi: 10.1182/asheducation-2018.1.576
Sandler SG, Tutuncuoglu SO. Immune thrombocytopenic purpura - Current management practices. Expert Opin Pharmacother. 2004;5:2515-2527. doi: 10.1517/14656566.5.12.2515
Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Exp RevHematol. 2019;12:685-698. doi: 10.1080/17474086.2019.1636645
Samuelsson A, Towers TerriL, Ravetch J. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:485-487. doi: 10.1126/science.291.5503.484
Nagrebetsky A, Al-Samkari H, Davis NM, Kuter DJ, Wiener-Kronish JP. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J Anaesth. 2019;122(1):19-31 . doi: 10.1016/j.bja.2018.09.010
Manasa K, Vani R. Influence of Oxidative Stress on Stored Platelets. Adv Hematol. 2016;2016: 4091461. doi: 10.1155/2016/4091461
Greenberg EM. Thrombocytopenia: a destruction of platelets. J Infus Nurs. 2017;40:41-50. doi: 10.1097/NAN.0000000000000204
Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33:85-93. doi: 10.1016/j.exphem.2004.09.006
Singh R, Masuda ES, Payan DG. Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors. J Med Chem. 2012;55:3614-3643. doi: 10.1021/jm201271b
Gulcin I. Antioxidants and antioxidant methods: an updated overview. Arch Toxicol. 2020;94:651-715. doi: 10.1007/s00204-020-02689-3
Forman HJ, Zhang H. Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021;20:689-709. doi: 10.1038/s41573-021-00233-1
Halliwell B and Gutteridge JMC. Free Radicals in Biology and Medicine. 5th Edition. New York: Oxford University Press; 2015. doi: 10.1093/acprof:oso/9780198717478.001.0001
Neha K, Haider MR, Pathak A, Yar MS. Medicinal prospects of antioxidants: A review. Eur J Med Chem. 2019;178:687-704. doi: 10.1016/J.EJMECH.2019.06.010
Bouayed J, Bohn T. Exogenous Antioxidants—Double-Edged Swords in Cellular Redox State: Health Beneficial Effects at Physiologic Doses versus Deleterious Effects at High Doses. Oxid Med Cell Longev. 2010;3:228-237. doi: 10.4161/oxim.3.4.12858
Bouaziz A, Romera-Castillo C, Salido S, et al. Cinnamtannin B-1 from bay wood exhibits antiapoptotic effects in human platelets. Apoptosis. 2007;12:489-498. doi: 10.1007/s10495-006-0014-z
Olas B, Saluk-Juszczak J, Wachowicz B. D-glucaro 1,4-lactone and resveratrol as antioxidants in blood platelets. Cell Biol Toxicol. 2008;24:189-199. doi: 10.1007/s10565-007-9028-8
Mithun M, Rajashekaraiah V. L-Carnitine as an additive in Tyrode's buffer during platelet storage. Blood Coagul Fibrinolys. 2018;29:613-621.
Rajashekaraiah V, Mithun M. A formulation of vanillic acid to enhance the platelet count during drug-induced thrombocytopenia. IPO Patent Application No. 201941020419; 2019.
Anjum V, Arora P, Ansari SH, Najmi AK, Ahmad S. Antithrombocytopenic and immunomodulatory potential of metabolically characterized aqueous extract of Carica papaya leaves. Pharm Biol. 2017;55:2043-2056. doi: 10.1080/13880209.2017.1346690
Gholamnezhad Z, Rouki V, Rezaee R, Boskabady MH. Medicago sativa ameliorated cyclophosphamide-induced thrombocytopenia and oxidative stress in rats. Toxin Rev. 2023;1:10. doi: 10.1007/s10565-007-9028-8
Leih Panopio ZB, Dalisay CG, Landicho JR, et al. Anti-thrombocytopenic activity of Amaranthus spinosus in ethanol-induced rat models exhibiting low platelet count. The Steth. 2015;9:1-19.
Abbas M, Saeed F, Arshad MU, et al. Exploring the therapeutic potential of apple extracts against thrombocytopenia in rat experimental models. Nutr Food Sci. 2018;48:397-405. doi: 10.1108/NFS-09-2017-0201
Saadia M, Rehman S, Robin S, et al. Potential of Nigella sativa seed aqueous extract in ameliorating quinine-induced thrombocytopenia in rats. Pak J Pharm Sci. 2017:30:1679-1690.
Dong XZ, Wang YN, Tan X, Liu P, Guo DH, Yan C. Protective effect of JXT ethanol extract on radiation-induced hematopoietic alteration and oxidative stress in the liver. Oxid Med Cell Longev. 2018;2018:9017835. doi: 10.1155/2018/9017835
Bandiola TMB, Corpuz MJT. Platelet and Leukocyte Increasing Effects of Syzygium cumini (L.) Skeels (Myrtaceae) Leaves in a Murine Model. Pharm Anal Acta. 2018;09:2018. doi: 10.4172/2153-2435.1000586
Asuquo Etim E, Abdulhakeem Adebayo Y, Emmanuel Ifeanyi O. Effect of Achyranthes Aspera Leaf Extract on Hematological Parameters of Swiss Albino Mice. World Journal of Public Health. 2019;4:96. doi: 10.11648/j.wjph.20190404.14
Uchechukwu O, Evelyn U. Body weight and platelet count changes in zidovudine administered Wistar albino rats 3 treated with ethanolic extracts of Annona muricata and Fagara zanthoxyloide. Int Blood Res Rev. 2019:9:1-18. doi: 10.9734/ibrr/2019/v9i330099
Nworie KM, Okorie AN, Ebere DN, Obike OC. Evaluation of antidote potential of methanol leaf extract of Bauhinia monandra on heparin-induced thrombocytopenia in mice. Biotechnologia. 2019;100:57-67. doi: 10.5114/bta.2019.83212
Ahmad A, Ibrahim M, Chester K, Khan W, Ahmad S, Ansari S. Antithrombocytopenic potential of bioactivity guided fractions of traditionally used Psidium guajava Linn. leaves in busulfan induced-thrombocytopenic rats. Pharmacogn Mag. 2019;15:440. doi: 10.4103/pm.pm_608_18
Bangayan JMB, Palattao JRM, Chua JMT, Capili JT, Ramirez Jr RB. Evaluation of Equisetum hyemale and Euphorbia hirta leaf extracts in increasing platelet count of sprague dawley rats. Int J Biosci. 2020;17(2):58-65. doi: 10.12692/ijb/17.2.58-65
Nyagolov Y, Pashalieva I, Stancheva E, Decheva L, Negrev N. Experimental data about melatonin effects on platelet count and functional activity. C R Acad Bulg Sci. 2012;65:855-860.
Ramsey H, Zhang Q, Wu MX. Mitoquinone restores platelet production in irradiation-induced thrombocytopenia. Platelets. 2015;26:459-466. doi: 10.3109/09537104.2014.935315
Singh VK, Kulkarni S, Fatanmi OO, et al. Radioprotective Efficacy of Gamma-Tocotrienol in Nonhuman Primates. Radiat Res. 2016;185:285-298. doi: 10.1667/RR14127.1
Zunjar V, Dash RP, Jivrajani M, Trivedi B, Nivsarkar M. Antithrombocytopenic activity of carpaine and alkaloidal extract of Carica papaya Linn. leaves in busulfan induced thrombocytopenic Wistar rats. J Ethnopharmacol. 2016;181:20-25. doi: 10.1016/j.jep.2016.01.035
Xia LM, Zhang AP, Zheng Q, et al. Quercetin-3-O-ß-D-glucuronide inhibits mitochondria pathway-mediated platelet apoptosis via the phosphatidylinositol-3-kinase/AKT pathway in immunological bone marrow failure. World J Tradit Chin Med. 2022;8:115-122. doi: 10.4103/wjtcm.wjtcm_44_21
Subenthiran S, Choon TC, Cheong KC, et al. Carica papaya leaves juice significantly accelerates the rate of increase in platelet count among patients with dengue fever and dengue haemorrhagic fever. eCAM. 2013;2013:616737. doi: 10.1155/2013/616737
Esmaeili A, Toosi NN, Taher M, Bayani M, Namazi J. Melatonin effect on platelet count in patients with liver disease. Gastroenterol Hepatol Bed Bench. 2021;14:356-361.
Elalfy MS, Elhenawy YI, Deifalla S, Hegazy M, Sabra A, Abdelaziz Y. Oxidant/antioxidant status in children and adolescents with immune thrombocytopenia (ITP) and the role of an adjuvant antioxidant therapy. Pediatr Blood Cancer. 2015;62:830-837. doi: 10.1002/pbc.25434
Rukoyatkina N, Shpakova V, Sudnitsyna J, et al. Curcumin at Low Doses Potentiates and at High Doses Inhibits ABT-737-Induced Platelet Apoptosis. Int J Mol Sci. 2021;22:5405. doi: 10.3390/ijms22105405
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
